Association between HER family expression and clinical outcomes with trastuzumab deruxtecan (T-DXd) in patients with hormone receptor–positive/HER2-negative (HR+/HER2-) metastatic breast cancer (mBC).
Year: 2026
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Shivani K. Thaker, Adam Dugan, Unnati Jariwala, Binyam Yilma, Michelle Weitz, Stamatina Fragkogianni, Samer Alkassis, Marla Lipsyc-Sharf, Alexis Ann LeVee, Yuan Yuan, Funda Meric-Bernstam, Hope S. Rugo, Joyce O'Shaughnessy, Mothaffar Rimawi, Rachel Schiff, David Elashoff, Martina Mcdermott, Amy Lauren Cummings, Jacob Mercer, Aditya Bardia
Institutions: University of California, Los Angeles, UCLA Health, UCLA Jonsson Comprehensive Cancer Center, Tempus Labs (United States), Cedars-Sinai Medical Center, The University of Texas MD Anderson Cancer Center, City Of Hope National Medical Center, Baylor University Medical Center, Baylor College of Medicine
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7162529558
Cites:
Cited by:
Related to: